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Abstract
Objective To compare perioperative outcomes following retroperitoneal robot-assisted partial nephrectomy (RPRAPN) and
transperitoneal robot-assisted partial nephrectomy (TPRAPN).
Methods With this Vattikuti Collective Quality Initiative (VCQI) database, study propensity scores were calculated according
to the surgical access (TPRAPN and RPRAPN) for the following independent variables, i.e., age, sex, side of the surgery,
RENAL nephrometry scores (RNS), estimated glomerular filtration rate (eGFR) and serum creatinine. The study's primary
outcome was the comparison of trifecta between the two groups.
Results In this study, 309 patients who underwent RPRAPN were matched with 309 patients who underwent TPRAPN.
The two groups matched well for age, sex, tumor side, polar location of the tumor, RNS, preoperative creatinine and eGFR.
Operative time and warm ischemia time were significantly shorter with RPRAPN. Intraoperative blood loss and need for
blood transfusion were lower with RPRAPN. There was a significantly higher number of intraoperative complications with
RPRAPN. However, there was no difference in the two groups for postoperative complications. Trifecta outcomes were
better with RPRAPN (70.2% vs. 53%, p < 0.0001) compared to TPRAPN. We noted no significant change in overall results
when controlled for tumor location (anteriorly or posteriorly). The surgical approach, tumor size and RNS were identified
as independent predictors of trifecta on multivariate analysis.
Conclusion RPRAPN is associated with superior perioperative outcomes in well-selected patients compared to TPRAPN.
However, the data for the retroperitoneal approach were contributed by a few centers with greater experience with this technique, thus limiting the generalizability of the results of this study.
Keywords Retroperitoneal · RAPN · Partial nephrectomy · Propensity matching

Introduction
Incidental detection of renal masses has increased in recent
times. Such incidentally detected renal masses are usually
smaller in size and are of early stage [1]. Partial nephrectomy (PN) has become the standard of care for treating such
incidentally detected small renal masses [2, 3]. Equivalent
* Gagan Gautam
gagangg@gmail.com
Extended author information available on the last page of the article

oncological and superior functional outcomes give an edge
to PN over radical nephrectomy (RN) [2–4]. There has been
a shift from open to minimally invasive PN due to perceived
benefits of less pain, lower blood loss and shorter hospital
stay [5, 6]. Robot-assisted partial nephrectomy (RAPN) has
become the preferred minimally invasive modality due to its
numerous advantages [6].
There is still a constant debate over the choice of surgical
access, i.e., retroperitoneal or transperitoneal. Both the surgical accesses have their advantages and disadvantages. This
debate is likely to persist in the absence of level I evidence.
Surgeons' experience and tumor location are major factors

13

Vol.:(0123456789)

2284

World Journal of Urology (2022) 40:2283–2291

in deciding the access mode. Posteriorly located tumors may
be more amenable for the retroperitoneal RAPN (RPRAPN)
approach and anterior for transperitoneal RAPN (TPRAPN).
However, this conjecture has been challenged by a study
reporting similar outcomes for both the surgical approaches
irrespective of tumor location [7]. Multiple studies have
been reported in the past decade comparing the two surgical approaches [7–16]. A systematic review of these studies
concluded that both the surgical approaches are equivalent in
a well-selected patient population operated by experienced
surgeons [17]. However, the level of evidence remains poor
due to the absence of a well-conducted randomized controlled trial.
Vattikuti Collective Quality Initiative (VCQI) is a multicentric and multinational database with data collected
from 18 centers across nine countries [8, 18, 19]. Thus, this
database provides the best opportunity to examine the two
surgical approaches in a multicentric setting in a diverse
patient population. In a previous study using this database,
Arora et al. compared 99 patients who underwent RPRAPN
with 394 patients who underwent TPRAPN [8]. Multiple
cases have been reported in the database during the last three
years. Therefore, this study aimed to update the comparison between the two groups for perioperative outcomes. We
also performed a propensity-matched analysis of the two
groups for the possible factors that could impact trifecta outcomes. We also aimed to study the impact of tumor location
(anterior/posterior) on outcomes following the two surgical
approaches.

Demographic variables

Materials and methods

We checked the normality of continuous data using Kolmogorov–Smirnov and Shapiro tests of normality. An independent sample Student’s t test was used if data were normally
distributed. Kruskal–Wallis test was used for non-normally
distributed variables. For categorical variables, Chi-square
tests or Fisher’s exact tests were used. Propensity scores
were calculated for dependent variable surgical access
(TPRAPN and RPRAPN) with independent variables of age,
sex, side of the surgery, RNS, baseline eGFR and creatinine
with trifecta as the primary outcome. Then 1:1 matching
was performed without replacements for each patient based
on propensity scores obtained with a caliper of 0.0001. All
the statistical tests were two-sided and performed with a significance level of p < 0.05. All the statistical analyses were
conducted using SPSS version 23 (IBM corporation, New
York, USA) and Stata (version 16; StataCorp, College Station, TX, USA) [22].

Vattikuti collective quality initiative (VCQI)
database
VCQI is a prospective web-based multi-institutional collaborative database for various robotic surgical procedures
[8, 18, 19]. Database for RAPN is contributed by 18 participating institutions from 9 countries (USA, UK, India, Italy,
Portugal, Belgium, Turkey, Australia and South Korea).
The database is Health Insurance Portability and Accountability Act (HIPAA) compliant, and ethics clearance was
obtained from each participating institution. From October
2014 to 2020, data of 3,801 patients who underwent RAPN
were contributed from the participating centers. Due to the
multi-institutional nature of the database, patients without adequate data had to be excluded from the study. After
excluding patients with incomplete data, 2,550 patients were
eligible for final analysis.
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For every patient, demographic variables such as age at the
time of surgery, sex (male/female), and body mass index
(BMI) were extracted. We also extracted data for clinical
variables such as tumor size, estimated glomerular filtration
rate (eGFR) using Modified diet in renal disease (MDRD)
equation, symptoms (absent/local/systemic), polar location
of the tumor (upper/middle/lower pole), number (single/
multiple), laterality (unilateral/bilateral), solitary kidney
and RENAL nephrometry score (RNS) [20].

Operative, postoperative and pathological factors
Data for operative factors such as surgical access (retroperitoneal/transperitoneal), operative time, warm ischemia
time, blood loss, intraoperative blood transfusion, need for
conversion to radical nephrectomy and intraoperative complications were also extracted. Complications were graded
as per Clavien–Dindo classification [21].
Primary endpoint
The primary endpoint of this study was the comparison of
trifecta outcomes between patients who underwent transperitoneal and retroperitoneal RAPN. Trifecta was defined as the
absence of complications, negative surgical margins, and
warm ischemia time less than 20 min or zero ischemia [18].

Statistical analysis
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Results
Baseline characteristics
Of the 2,550 patients included in this study, 326 (12.8%)
underwent RPRAPN and 2,224 (87.2) underwent TPRAPN.
Mean age of the patients included in this study was
57.6 years. There were 65.3% males and 34.7% females.
Mean BMI, tumor size and CCI were 28.6 kg/m2, 34.6 cm
and 1.25, respectively. Most of the included patients were
asymptomatic at presentation (84.2%). About 2.6% of the
included patients has a single kidney. Preoperative hemoglobin, creatinine and eGFR were 13.8 gm/dL, 0.97 mg/dL
and 80.5 ml/min, respectively. Most of the included tumors
were of low (41.3%) or intermediate complexity (49.1%)
as per RNS. Intraoperative complication, blood transfusion
and conversion to radical nephrectomy were needed in 4.7%,
3.1% and 1.6% of the patients, respectively. Overall complications, positive surgical margins and trifecta outcomes
were noted in 8.8%, 3% and 55.1% of the patients, respectively. Baseline comparison (prematching) of the two surgical approaches is provided in Table 1

Postmatching
There was statistically significant difference between the
two groups for age, BMI, tumor size and preoperative eGFR
before matching. After 1:1 matching, the two surgical groups
matched well for age, sex, tumor side, tumor location, RNS,
preoperative serum creatinine and eGFR (Table 2). Of the
326 patients who underwent RPRAPN, propensity matching
in a 1:1 ratio was possible for 309 patients. Clinical tumor
size and Charlson comorbidity index were significantly
higher in the TPRAPN group (Table 2). At the same time,
preoperative hemoglobin and BMI were significantly higher
in the RPRAPN group. Compared to the TPRAPN group,
tumors in the RPRAPN group were more likely to be posteriorly located (75.2% vs. 38.8%, p = 0.000). Operative time
and WIT were significantly shorter with RPRAPN. Intraoperative blood loss and need for blood transfusion were
lower with RPRAPN. There were significantly higher intraoperative complications with RPRAPN (Table 3). However,
there was no difference in the two groups for postoperative
complications. Trifecta outcomes were significantly better
with RPRAPN (70.2% vs. 53%, p = 0.000) (Table 3).

Comparsion of outcomes with tumor location
We noted no significant change in overall results when
comparing anterior tumors managed with TPRAPN and
posterior tumors with RPRAPN (Supplementary table 1).
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Subgroup comparison of anterior and posterior tumors also
revealed similar results (Supplementary tables 2 and 3).

Predictors of trifecta
We considered age, BMI, sex, RNS, surgical approach,
tumor size, location, face of tumor and eGFR for prediction
of trifecta in the matched patient cohort. The multivariate
logistic regression analysis identified tumor size, RNS and
surgical approach as independent predictors (Table 4).

Discussion
Partial nephrectomy has become a standard treatment
option for managing patients with localized small renal
masses [2]. Advances in surgical technique and equipment
have allowed for satisfactory resection of many complex
renal masses. With the dissemination of robotic technology and training programs across the globe, most of the
partial nephrectomies are today performed robotically.
Choice of surgical access in a given situation depends
upon patient factors, tumor-related factors and surgeon
experience [14]. The retroperitoneal approach allows
direct access to the kidney without breaching the peritoneum, thereby reducing intestinal injury risk [14]. It also
provides direct access to the renal artery and posteriorly
located tumors without the need for flipping the kidney
[14]. However, unfamiliar anatomy and limited working
space are some of the limitations. Furthermore, due to the
lack of proven benefit of one mode of access over another,
choice in a given situation usually depends on surgeons’
experience and familiarity with a particular space. This
multicentric propensity-matched analysis of RPRAPN and
TPRAPN provides the most extensive comparison of the
two groups to the best of our knowledge.
We matched the two surgical groups for all the baseline
factors that could influence the trifecta outcomes. We performed propensity matching for age, sex, side of the surgery, RNS, baseline eGFR and creatinine between the two
groups. The two surgical groups were well matched for
baseline characteristics except for BMI, clinical tumor size
and CCI. BMI was significantly higher in the RPRAPN.
Obesity could add to the surgical complexity, especially
in the retroperitoneal route due to excessive fat deposition. However, we concede that the difference in BMI
noted may be statistically significant but not clinically relevant (mean difference 1.4). Tumor size was significantly
larger in the TPRAPN group. We did not consider this
variable for propensity matching as it is known that RNS
(that incorporates tumor size) is much more comprehensive in predicting the tumor complexity [20]. We did not

13

2286

World Journal of Urology (2022) 40:2283–2291

Table 1  Comparison of two surgical groups for the overall patient cohort
Variable

Overall (n = 2550)

Retroperitoneal (n = 326)

Transperitoneal (n = 2224)

p-value

Age (mean ± SD)
Sex
Male
Female
BMI (Kg/m2)
Tumor size (mean ± SD) mm
CCI (mean ± SD)
Clinical symptoms
Asymptomatic
Local
Systemic
Single kidney
Tumor side
Right
Left
Face of tumor
Anterior
Posterior
Polar location of tumor
Upper
Mid
Lower
Preoperative hemoglobin (gm/dL)
Preoperative creatinine (mg/dL)
Preoperative eGFR
Renal nephrometry score (Mean ± SD)
RENAL complexity
Low
Moderate
High
Operative time
Warm ischemia time
Blood loss ml (Median with range)
Intraoperative transfusion
Intraoperative complication
Need for conversion to radical nephrectomy
Postoperative complications
Grade I
Grade II
Grade III
Grade IV
Positive margin
Trifecta

57.6 ± 12.9

60.3 ± 11.6

57.3 ± 13.1

0.000

1666(65.3%)
884(34.7%)
28.6 ± 6
34.6 ± 16.8
1.25 ± 1.4

210 (64.4%)
116(35.5%)
29.7 ± 6
30.9 ± 14.1
1.3 ± 1.5

1456 (65.4%)
768(34.5%)
28.4 ± 6
35.1 ± 17.1
1.25 ± 1.46

0.710

2148(84.2%)
371(14.5%)
31(1.2%)
67(2.6%)

242 (74.2%)
75 (23%)
9(2.76%)
11 (3.3%)

1906 (85.7%)
296(13.3%)
22(0.9%)
56 (2.5%)

13.01(51%)
1249(49%)

158 (48.4%)
168 (51.6%)

1091 (49%)
1133 (51%)

0.842

1392(54.6%)
1158(45.4%)

65 (19.9%)
261 (80%)

1327 (59.6%)
897(40.4%)

0.000

818(32.1%)
951(37.3%)
781(30.6%)
13.8 ± 1.6
0.97 ± 0.38
80.5 ± 24.1
6.99 ± 1.84

100 (30.6%)
130 (39.8%)
96 (29.4%)
14.1 ± 1.6
1.00 ± 0.28
76.3 ± 22
7.05 ± 1.85

718 (32.2%)
821 (36.9%)
685 (30.8%)
13.7 ± 1.6
0.97 ± 0.39
81.2 ± 24.4
6.98 ± 1.84

1052(41.3%)
1252(49.1%)
246(9.6%)
189.6 ± 66
18.1 ± 11.4
100(10–9650)
78(3.1%)
121(4.7%)
40 (1.6%)
224(8.8%)
114(4.5%)
53(2.1%)
43 (1.7%)
14(0.6%)
76(3%)
1406(55.1%)

126 (38.6%)
168 (51.5%)
32 (9.8%)
163.4 ± 52.7
16.1 ± 8.4
50 (10–1600)
2 (0.6%)
39 (11.9%)
6(1.8%)
21 (6.4%)
6 (1.8%)
8 (2.4%)
7 (2.1%)
0
8 (2.4%)
228 (69.9%)

926 (41.6%)
1084 (48.7%)
214 (9.6%)
194.1 ± 67.1
18.45 ± 11.7
100 (10–9650)
76 (3.4%)
82 (3.6%)
34 (1.52%)
203 (9.1%)
108 (4.8%)
45 (2.0%)
36 (1.6%)
14 (0.6%)
68 (3.05%)
1178 (52.9%)

0.000
0.000
0.535

0.000
0.367

0.586
0.000
0.281
0.000
0.543

0.584
0.000
0.001
0.000
0.006
0.000
0.671
0.754
0.118

0.550
0.000

SD standard deviation, BMI body mass index, eGFR estimated glomerular filtration rate, CCI Charlson comorbidity index

perform matching for the face of the tumor as this could
theoretically favor one approach over another. However,
Dell’Oglio et al. reported no advantage for TPRAPN for
treating anterior tumors and RPRAPN for posterior tumors
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[7]. The authors reported equivalent outcomes for both
surgical approaches irrespective of the tumor location [7].
Similarly, we did not find any change in overall results
after adjusting tumor location for the surgical access. The

World Journal of Urology (2022) 40:2283–2291
Table 2  Comparison of baseline
characteristics between the two
surgical groups
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Variable

Transperitoneal
(n = 309)

Retroperitoneal
(n = 309)

p-value

Age (mean ± SD)
Sex
Male
Female
BMI (Kg/m2)
Tumor size (mean ± SD) mm
CCI (mean ± SD)
Clinical symptoms
Asymptomatic
Local
Systemic
Single kidney
Tumor side
Right
Left
Face of tumor
Anterior
Posterior
Polar location of tumor
Upper
Mid
Lower
Preoperative hemoglobin (gm/dL)
Preoperative creatinine (mg/dL)
Preoperative eGFR
Renal nephrometry score (Mean ± SD)
RENAL complexity
Low
Moderate
High
Number of lesions operated
1
2
3
6

60.4 ± 10.6

59.9 ± 11

0.644

216 (69.9%)
93 (30.1%)
28.5 ± 8.8
35.8 ± 17.7
1.6 ± 1.2

205 (66.3%)
104 (33.6%)
29.9 ± 6
30.6 ± 14.1
1.2 ± 1.5

0.342

271 (87.7%)
34 (11%)
4 (1.3%)
10 (3.2%)

232 (75.1%)
68 (22%)
9 (2.9%)
11 (3.5%)

159 (51.4%)
150 (48.6%)

158 (51.1%)
151 (48.9%)

0.936

189 (61.1%)
120 (38.9%)

62 (20.1%)
247 (79.9%)

0.000

97 (31.4%)
112 (36.2%)
100 (32.3%)
13.7 ± 1.5
1.03 ± 0.47
78 ± 23
7.06 ± 1.87

97 (31.3%)
123 (39.8%)
89 (28.8%)
14.2 ± 1.6
1.0 ± 0.29
76.7 ± 22
7.00 ± 1.8

120 (38.8%)
156 (50.4%)
33 (10.6%)

123 (39.8%)
158 (51.1%)
28 (9.06%)

292 (94.4%)
11 (3.55%)
5 (1.6%)
1 (0.3%)

287(92.8%)
16 (5.2%)
6 (1.9%)
0

0.001
0.000
0.000

0.000
0.824

0.561
0.000
0.420
0.124
0.786

0.795

0.560

SD standard deviation, BMI body mass index, eGFR estimated glomerular Filtration rate, CCI Charlson
comorbidity index

findings of the present updated study are different from
the previous VCQI database analysis [8]. This study noted
RPRAPN associated with significantly shorter operative
time and WIT. Intraoperative blood loss and the need for
intraoperative transfusion were significantly higher in the
TPRAPN group. Overall complications and positive surgical margins were similar in the two groups in the present
study.
There was no difference in the two groups for operative time and WIT for the previous VCQI database study.
In a multicentric matched analysis of 352 patients who

underwent TPRAPN or RPRAPN by Harke et al [10],
authors noted RPRAPN associated with significantly shorter
operative time and WIT. Takagi et al. in a single-center study
of RAPN for laterally located tumors noted comparable findings [15]. Two other multicenter propensity-matched studies
have reported operative times favoring RPRAPN; however,
WIT was similar in these two studies [11, 12]. The largest meta-analysis on the topic by Zhou et al. also reported
shorter operative times with RPRAPN and comparable WIT
[16].
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Table 3  Comparison of perioperative outcomes following retroperitoneal and transperitoneal robot-assisted partial nephrectomy
Variable

Transperitoneal (n = 309)

Retroperitoneal (n = 309)

p-value

Operative time
Warm ischemia time
Blood loss ml (Median with range)
Intraoperative transfusion
Intraoperative complication
Conversion to open
Gross violation of tumor bed
Injury to abdominal organs
Major bleeding from tumor vessel
Unknown
Need for conversion to radical nephrectomy
Postoperative complications
Grade I
Grade II
Grade III
Grade IV
Positive margin
Trifecta

191.1 ± 70.4
18.4 ± 10
150 (10–9650)
10 (3.2%)
8 (2.6%)
0
5
1
2
0
6(1.9%)
23 (7.4%)
11 (3.5%)
4 (1.3%)
7 (2.2%)
1 (0.3%)
7
164 (53%)

163.7 ± 54.1
16.1 ± 8.5
50 (10–1600)
2 (0.6%)
37 (12%)
0
34
0
2
1
5 (1.6%)
21 (6.8%)
6 (1.9%)
8 (2.6%)
7 (2.2%)
0
8
217 (70.2%)

0.000
0.002
0.000
0.02
0.000

Table 4  Multivariate analysis to
identify predictors of the trifecta

0.671
0.754
0.432

0.794
0.000

Trifecta

OR

Lower limit of CI

Upper limit of CI

p-value

Age
BMI
CCI
Clinical tumor size
eGFR
Tumor location
Upper
Mid
Lower
RNS
Tumor face
Anterior
Posterior
Access
Retroperitoneal
Transperitoneal

1.14
1.001
0.989
0.974
0.999

0.74
0.982
0.957
0.960
0.990

1.74
1.021
1.021
0.988
1.008

0.549
0.908
0.480
0.000
0.885

0.831
0.776
Reference
0.805

0.504
0.470

1.370
1.281

0.467
0.322

0.710

0.912

0.001

Reference
0.914

0.588

1.420

0.688

Reference
0.611

0.397

0.941

0.025

BMI body mass index, eGFR estimated glomerular filtration rate, CI confidence interval, OR Odds ratio,
Charlson comorbidity index

Regarding blood loss, our findings are similar to previous studies by Takagi et al [15], Arora et al [8] and Mittakanti et al [11]. However, Paulucci et al [12] reported comparable blood loss in the two groups in their study. Data
for intraoperative blood transfusion were not reported in
any of these studies. Interestingly, we noted a significantly
higher risk of intraoperative complications in patients
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undergoing RPRAPN. The most common complication
was a gross violation of the tumor bed, and none of the
patients required conversion to open in either group. Furthermore, the need for conversion to radical nephrectomy
was similar in the two groups. In a multicentric study by
Porpiglia et al. authors compared perioperative outcomes
following transperitoneal or retroperitoneal minimally

World Journal of Urology (2022) 40:2283–2291

invasive PN [13]. In contrast to the present study, these
authors reported higher intraoperative complications in the
transperitoneal group. However, a significant proportion
of the patients in this study had undergone laparoscopic
surgery; therefore, results may not be comparable to ours.
These findings noted in the current research align with
the results of previously published literature [7–13, 15, 17].
However, the trifecta outcomes were significantly higher
in patients of the RPRAPN group. No impact on trifecta
outcomes was noted even after controlling for the face of
the tumor. Interestingly, the surgical approach remained an
independent predictor of trifecta on multivariate analysis
along with tumor size and RNS. This remains a novel finding of this study to the best of our knowledge. Literature on
reporting consolidated outcomes such as trifecta or pentafecta following RPRAPN is limited. Carbonara et al. [9] in
their study noted similar trifecta outcomes between the two
groups. Similarly, Choi et al. [23] in their cohort of patients
who underwent RPRAPN or TPRAPN, noted comparable
pentafecta outcomes. However, the definition of trifecta or
pentafecta outcomes used in these studies differs from ours.

Limitations
Despite being one of the largest series comparing RPRAPN
and TPRAPN, this study has some limitations. Firstly, due to
multicentric nature of database, surgical technique was not
described in this study. Additionally, surgical skills and surgeon experience were variable. RPRAPN has been less preferred surgical technique with only 326 cases being reported
from 18 centers over 6 years of time period. On exploratory
analysis of our database, we noted that only a few centers
had contributed to the data for RPRAPN to the VCQI database. Therefore, despite showing superior results, the use
of this surgical technique is limited to those centers where
surgeons are familiar with this technique. Secondly, there
are certain limitations of the VCQI database related to lack
of data on other treatment options, previous surgical history
anesthesia and drain placement. Previous studies from the
RAPN VCQI database have highlighted these limitations
[8, 18, 19]. Thirdly, details of surgical technique such as
tumor excision or enucleation are lacking in the database.
Fourthly, another important limitation to consider is inequality of matched groups for BMI and tumor size. Tumor size is
an important factor defining the complexity of renal masses.
However, it is not the alone factor and RNS provides the
more comprehensive data on tumor complexity. We did not
consider BMI as a factor for matching as most of the previous studies have not reported BMI to be a predictor of
trifecta outcomes following RAPN [24–27]. Lastly, due to
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the current study's retrospective nature, the possibility of
selection bias cannot be eliminated.

Conclusion
This multicentric propensity-matched study showed that
RPRAPN is associated with superior perioperative outcomes
in well-selected patients compared to TPRAPN. Location of
tumor (anteriorly or posteriorly) does not influence perioperative outcomes following RPRAPN. Surgical access (transperitoneal or retroperitoneal) is an independent predictor of
the trifecta outcomes.
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